April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Jill Feldman Awarded the 2024 ASCO Patient Advocate Award
Mar 24, 2024, 13:03

Jill Feldman Awarded the 2024 ASCO Patient Advocate Award

The American Society of Clinical Oncology (ASCO) has announced Jill Feldman, as the recipient of the 2024 ASCO Patient Advocate Award. This award acknowledges Dr. Newman’s dedication and contributions to the field of global oncology.

Jill Feldman, is a lung cancer patient and passionate advocate with a personal connection to the cause. With a family history of the disease, she became involved in lung cancer advocacy in its infancy in 2001. In 2009, at age 39 with four small children, Ms. Feldman herself was diagnosed with EGFR-positive lung cancer. Ms. Feldman’s advocacy focuses on patient-centred research and care, notably serving as past chair of the International Association for the Study of Lung Cancer’s Patient Advisory Board, a member of the programmatic panel for the U.S. Department of Defense Lung Cancer Research Program, a member of the ECOG-ACRIN Research Group’s Patient Advocate Committee and Thoracic Committee, and as the patient advocate on the National Lung Cancer Round Table Steering Committee.

She co-founded the EGFR Resisters, a community committed to accelerating research and providing support and best practices for patients and families. Ms. Feldman serves in various other leadership roles, striving to humanize the narrative around lung cancer research and care. She emphasizes the importance of considering the profound impact of the disease on patients and families beyond statistics and survival. She also strongly advocates for embedding a health equity lens in all aspects of research and care.

About the ASCO Patient Advocate Award 

First awarded in 2003, this award recognizes an individual involved in patient advocacy activities that impact public awareness about cancer, its causes, cures, or treatment, or activities that result in additional support either legislatively or fiscally for cancer research, treatment, prevention or care.

The oncology community and our team at OncoDaily extend our congratulations to Jill Feldman on this deserving accolade, which highlights her significant impact on patient advocacy.